IDEAYA Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for IDEAYA Biosciences (IDYA).

Price Target Range — 12 Quarters

Analyst Consensus — 20 Analysts

2S.Buy

16Buy

2Hold

Consensus RatingBuy# Analysts20Avg. Consensus PT$52Upside to Avg. PT+36.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Guggenheim	Paul Jeng	PT Raise	Buy	$54→$57
Sep 1, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$42
Aug 5, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$63→$59
Aug 5, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$58→$60
Jul 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$53→$48
Jul 7, 2026	Truist Securities	Gregory Renza	PT Cut	Buy	$65→$63
Jun 12, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$58
Jun 2, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$58
May 7, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$52→$50
Apr 14, 2026	Goldman Sachs	Corinne Jenkins	PT Raise	Neutral	$31→$35
Apr 14, 2026	Wells Fargo	Eva Fortea Verdejo	PT Raise	Overweight	$44→$48
Apr 14, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$49→$53
Apr 14, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$52→$58
Apr 14, 2026	Guggenheim	Paul Jeng	PT Raise	Buy	$50→$54
Mar 31, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$52
Feb 19, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$64→$65
Feb 18, 2026	RBC Capital	Leonid Timashev	Maintained	Outperform	$49
Feb 18, 2026	Guggenheim	Paul Jeng	Maintained	Buy	$50
Feb 18, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$49→$52
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$41→$45

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and maintains $42 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $65 to $63.

Benzinga Newsdesk

IDEAYA Biosciences Inc

IDEAYA Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

PRO
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63

People Also Watch

People Also Watch

IDEAYA Biosciences Inc

IDEAYA Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

PROCitizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

PROTruist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

PROWedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

PRORBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

PROTruist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57

PRO
Citizens Reiterates Market Outperform on IDEAYA Biosciences, Maintains $42 Price Target

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

PRO
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60

PRO
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

PRO
Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $63